Roivant Sciences Ltd. (ROIV)
Nasdaq: ROIV · Pharmaceutical Preparations · London · filing with the SEC since 2015
Grade5.3
◀ Past 6.1● Present 6.5▶ Future 3.6
Who owns Roivant Sciences Ltd.
As filed with the SECHolders of 5% or more
3
Fmr LLC holds 10.3% of COMMON STOCK, as its SCHEDULE 13G/A filed Mar 6, 2026 says.
Directors and officers
15
report now, of 21 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Mar 6, 2026 · COMMON STOCK · 9.5% in Feb 5, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock
Morgan Stanley
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Shares · 6.9% in May 12, 2026
QVT Financial LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common shares, par value $0.0000000341740141 per share · reported falling below 5%, from 9.22% in Feb 14, 2025
Ramaswamy Vivek
SCHEDULE 13G/A · filed May 6, 2026 · Common Shares · reported falling below 5%, from 6.8% in Feb 13, 2026
Viking Global Investors LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Shares, $0.0000000341740141 par value per share · reported falling below 5%, from 5.02% in Aug 14, 2025
SB Investment Advisers (UK) Limited
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Shares, par value $0.0000000341740141 per share · reported falling below 5%, from 5.8% in Nov 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What ROIV reports owning in othersstakes of 5% or more, and other ties
Immunovant, Inc. IMVT
SCHEDULE 13D/A · filed Dec 12, 2025 · Common Stock, par value $0.0001 per share
Arbutus Biopharma Corporation ABUS
SCHEDULE 13D/A · filed Oct 5, 2026 · Common Shares, without par value
Other ties the annual report names
Immunovant, Inc.
An entity · consolidated entity · owns, named in the 10-K filed May 20, 2026
Arbutus Biopharma Corporation
An investee · investee · invested in, named in the 10-K filed May 20, 2026
Datavant
An investee · investee · invested in, named in the 10-K filed May 20, 2026
Datavant Holdings, Inc
An investee · investee · invested in, named in the 10-K filed May 20, 2026
19 subsidiaries in 4 countries, from the list filed with the 10-K filed May 20, 2026.
Insider tradesForm 4
123sales
0purchases
31sales on a scheduled plan
12people selling
$915Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 41 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Manchester Keith S | director | 20 | $155M | 0 | 0 | $0 |
| Gold Daniel Allen | director | 19 | $147M | 0 | 0 | $0 |
| Qvt Financial LP | director | 19 | $147M | 0 | 0 | $0 |
| Sukhatme Mayukh | President & CIO | 13 | $109M | 0 | 0 | $0 |
| Ramaswamy Vivek | director | 6 | $106M | 0 | 0 | $0 |
| Venker Eric | President & Immunovant CEO | 20 | $95.0M | 18 | 0 | $0 |
| Torti Frank | President and Vant Chair | 3 | $82.0M | 3 | 0 | $0 |
| Gline Matthew | CEO | 4 | $46.2M | 0 | 0 | $0 |
| Pulik Richard | CFO | 6 | $21.6M | 0 | 0 | $0 |
| Fitzgerald Meghan | director | 5 | $3.3M | 4 | 0 | $0 |
| Epperly Melissa B, | director | 7 | $2.6M | 6 | 0 | $0 |
| Humes Jennifer | Chief Accounting Officer | 1 | $400,000 | 0 | 0 | $0 |